Skip to main content
Premium Trial:

Request an Annual Quote

Swiss Aren’t Neutral on Proteomics

Premium

Swiss company Geneva Proteomics was rumored to be negotiating a joint venture with Celera, but now that it has secured $40 million in financing, the company’s officers figure that instead they’ll compete.

GeneProt’s founders, who have ties with Geneva Bioinformatics (GeneBio) and the Swiss Institute of Bioinformatics, a leading developer of proteomics software, say they will build the “world’s first dedicated proteomics factory.”

Keith Rose, chief scientific officer, said GeneProt is “producing and accumulating massively parallel proteomic data” and “concentrating most of its effort on making the factory production process as robust as possible” in order to have one or two proteomes completed by the end of next year. GeneProt’s technology will separate and identify proteins using enzymes to cut them into small pieces and laser mass spectrometry for analysis. By first quarter 2001, the company intends to have 50 mass spectrometers in place.

But other proteomics explorers are using similar methodology to the same ends. The process has even already been partially robotized by the UK’s Oxford GlycoSciences and Large Scale Biology, in Vacaville, Calif.

Asked how he hopes to fare against the well-funded competition, GeneProt’s president Robin Offord said, “There’s room for everybody. There are over 256 tissues and more than 1,000 diseases.” If each of those has a proteomic profile there will be room for many more competitors.

Reporting by Adrienne Burke, Sandra Katzman, Christopher Maggos, and Dennis Waters

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.